HeartWare International Inc. moved quickly to launch the HeartWare Ventricular Assist Device (HVAD) in the U.S after FDA approved last November as a bridge to heart transplant for patients with end-stage heart failure.
During HeartWare’s fourth-quarter earning’s call on Feb. 27, CEO Evan Godshall reported the company sold 134 HVAD systems in the U.S., contributing to a record 345 systems sold globally during...